Please assess the completion status of the following clinical trial:

Trial Title: Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Burn injury comprising 2nd degree deep partial thickness and/or 3rd degree full thickness burns, ≥20% total body surface area with expected need for surgical intervention and not exceeding the sum of age plus burn size of 100 (Baux score)~* Dosing must occur within 8-12 days post-burn~* Subjects must weigh at least 45kgs (for group 1 with doses of 0.03mg/kg) and be under 100 kg to participate in the study~Exclusion Criteria:~* Spinal cord injury~* Hypoxic brain injury (Glasgow Coma Scale (GCS) \<8) at screening~* True conductive electric burn with suspected neurologic injury~* Uncontrolled diabetes with HbA1c \> 10% at screening, or known history of hypoglycemia,~* History of or active peripheral neuropathy or seizure disorder~* Systemic corticosteroids : \> 10mg/d of prednisone or equivalent, other investigational treatments (excluding investigational dressings), medications for weight loss including megestrol acetate, androgens or oral beta agonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- BVS857 Grp 1A open label (Type: EXPERIMENTAL): 0.03 mg/kg of BVS857intravenously in open label manner
- BVS857 Group 1B/1C, 2, 3, 4 Double Blind (Type: EXPERIMENTAL): None
- Placebo Group 1B/1C, 2, 3, 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).